Summary of Late-Breaking Drug Trials at ACC.25 , major breakthroughs in cardiovascular pharmacology were presented:
\n\u2022 Semaglutide (GLP-1 RA):
\n\u2022 STRIDE trial: Showed significant improvement in symptoms and walking distance in patients with peripheral artery disease (PAD) \u2014 first such therapy in over 20 years. This marks the first major therapeutic advance in the treatment of PAD since cilostazol and supervised exercise therapy introduced decades ago.
\n\u2022 SOUL trial: Oral semaglutide showed modest cardiovascular benefits compared to the injectable formulations ; still important for needle-averse patients.
\n\u2022 Api-CAT trial:
\n\u2022 Demonstrated that low-dose apixaban in cancer patients with VTE offers similar efficacy to standard dose but with lower bleeding risk.
\n\u2022 WARRIOR trial:
\n\u2022 Intensive medical therapy in women with INOCA was neutral in outcomes, but emphasized continued use of statins and ACEs\/ARBs, and highlighted the need for further research.
\n\u2022 Lorundrostat:
\n\u2022 A new aldosterone synthase inhibitor showed strong blood pressure reduction in resistant hypertension (Phase 2B), with promise for future use.
\n\u2022 REVERSE-IT trial:
\n\u2022 Bentracimab, a reversal agent for ticagrelor, showed effectiveness in managing major bleeding \u2014 offering a critical safety option.<\/p>\n
Quote from Dr. Richard Kovacs (ACC CMO):
\nThis year\u2019s trials bring long-awaited tools for underserved conditions like PAD and resistant hypertension.<\/p>\n","protected":false},"excerpt":{"rendered":"
Summary of Late-Breaking Drug Trials at ACC.25 , major breakthroughs in cardiovascular pharmacology were presented: \u2022 Semaglutide (GLP-1 RA): \u2022 STRIDE trial: Showed significant improvement in symptoms and walking distance in patients with peripheral artery disease (PAD) \u2014 first such therapy in over 20 years. This marks the first major therapeutic advance in the treatment […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6382","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6382"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6382\/revisions"}],"predecessor-version":[{"id":6383,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6382\/revisions\/6383"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}